Our team’s reading recommendation for this month goes to “Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis” by Gelmon et al., an extremely interesting paper just published in “The European Journal of Cancer”.
Germline BRCA1 and BRCA2 mutations are well known for their implication in breast cancer as they’re reported to account for 5% of all of them, with a higher prevalence in patients with a family history of breast cancer. Olaparib, a PARP inhibitor, is a targeted treatment for patients with BRCA1 and BRCA2 mutations, (HER2)-negative advanced/metastatic breast cancer. Its clinical effectiveness as a monotherapy was assessed in a randomized phase III trial resulting in a significantly increased progression-free survival compared with chemotherapy treatment of physician’s choice.
Based on these promising results, a second study, the phase IIIb LUCY trial assessed the clinical effectiveness of olaparib in similar patients, in a setting reflecting clinical practice. The interim analysis presented in this paper confirms, on 252 patients, the previous results in this real-world setting both in terms of effectiveness and in terms of safety.
This, once again, demonstrates the importance of precision in diagnostics to offer cancer patients the best possible therapy.
We at 4bases are proud to develop and offer molecular diagnostic tools to identify, in real-world clinical settings, gene mutations in breast and ovary cancer, like with our BRaCA screen clinically validated CE-IVD kit.
 Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O’Shaughnessy J; Collaborating Investigators. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Eur J Cancer. 2021 Jul;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1. PMID: 34087573.